Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Wave Life Sciences (WVE) Cash from Financing Activities (2016 - 2025)

Wave Life Sciences (WVE) has disclosed Cash from Financing Activities for 11 consecutive years, with $439.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Financing Activities rose 1156.95% year-over-year to $439.7 million, compared with a TTM value of $488.2 million through Dec 2025, up 92.3%, and an annual FY2025 reading of $488.2 million, up 92.3% over the prior year.
  • Cash from Financing Activities was $439.7 million for Q4 2025 at Wave Life Sciences, up from $32.7 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $439.7 million in Q4 2025 and bottomed at $17000.0 in Q3 2022.
  • Average Cash from Financing Activities over 5 years is $49.9 million, with a median of $10.2 million recorded in 2021.
  • The sharpest move saw Cash from Financing Activities surged 177757.89% in 2021, then crashed 99.84% in 2022.
  • Year by year, Cash from Financing Activities stood at $33.8 million in 2021, then plummeted by 99.84% to $55000.0 in 2022, then soared by 170740.0% to $94.0 million in 2023, then tumbled by 62.77% to $35.0 million in 2024, then surged by 1156.95% to $439.7 million in 2025.
  • Business Quant data shows Cash from Financing Activities for WVE at $439.7 million in Q4 2025, $32.7 million in Q3 2025, and $11.7 million in Q2 2025.